References
- Pan XR, Yang WY, Li GW, et al. Prevalence of diabetes and its risk factors in China, 1994. Diabetes Care 1997;20:1664-9
- National Diabetes Research Group. Diabetes mellitus survey of 300,000 in fourteen provinces and cities of China. Chin Med J 1981;20:678-81
- Gu D, Reynolds K, Duan X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 2003;46:1190-8
- Yang W, Lu J, Weng J, et al. China National Diabetes and Metabolic Disorders Study Group. Prevalence of diabetes among men and women in China. N Engl J Med 2010;362:1090-101
- American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2003;26(Suppl 1):S33-50
- UKPDS Group. UK Prospective Diabetes Study 7: response of fasting plasma glucose to diet therapy in newly presenting Type II diabetic patients. Metabolism 1990;39:905-12
- Stephen N. Davis. The role of glimepiride in the effective management of Type 2 diabetes. J Diabetes Complications 2004;18:367-76
- Inukai K, Watanabe M, Nakashima Y, et al. Efficacy of glimepiride in Japanese type 2 diabetic subjects. Diabetes Res Clin Pract 2005;68:250-7
- Luis Bautista J, Bugos C, Dirnberger G, et al. Efficacy and safety profile of glimepiride in Mexican American Patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. Clin Ther 2003;25:194-209
- Kabadi MU, Kabadi UM. Effects of glimepiride on insulin secretion and sensitivity in patients with recently diagnosed type 2 diabetes mellitus. Clin Ther 2004;26:63-9
- China Diabetes Society. China Guideline for Type 2 Diabetes. Chin J Endocrinol Metab 2008;24
- Li Y, Zhao W, Luo B, et al. Clinical evaluation of efficacy and safety of glimepiride in the treatment of type 2 diabetes. Chin J Endocrinol Metab 2002;18:152-5
- Zhang Q, Yu D, Li J, et al. Improvement of insulin sensitivity by adding on glimepiride in type 2 diabetes patients poorly controlled with sub-maximal insulin dose. Chin J Endocrinol Metab 2010;26:1031-4
- Lu Z, Pan C, Chen J, et al. Efficacy and safety of insulin glargine combined with glimepiride in type 2 diabetic patients with poor glycemic control. Chin J Endocrinol Metab 2009;25:617-21
- Malerczyk V, Badian M, Korn A, et al. Dose linearity assessment of glimepiride (Amaryl) tablets in healthy volunteers. Drug Metabol Drug Interact 1994;11:341-57
- Goldberg RB, Holvey SM, Schneider J. A dose–response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. Diabetes Care 1996;19:849-56
- Reusch JE, Draznin BB. Atherosclerosis in diabetes and insulin resistance. Diabetes Obes Metab 2007;9:455-63
- Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
- Kardas P. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes). Diabetes Obes Metab 2005;7:722-8
- Schade DS, Jovanovic L, Schneider J. A placebo-controlled, randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J Clin Pharmacol 1998;38:636-41
- Rosenstock J, Samols E, Muchmore DB, et al. Glimepiride, a new once daily sulfonylurea a double blind placebo-controlled study of NIDDM patients. Diabetes Care 1996;11:1194-9